KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Accounts Payables (2016 - 2025)

Thermo Fisher Scientific's Accounts Payables history spans 17 years, with the latest figure at $3.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 17.64% year-over-year to $3.6 billion, compared with a TTM value of $3.6 billion through Dec 2025, up 17.64%, and an annual FY2025 reading of $3.6 billion, up 17.64% over the prior year.
  • Accounts Payables for Q4 2025 was $3.6 billion at Thermo Fisher Scientific, up from $3.1 billion in the prior quarter.
  • The five-year high for Accounts Payables was $3.6 billion in Q4 2025, with the low at $2.1 billion in Q3 2021.
  • Average Accounts Payables over 5 years is $2.7 billion, with a median of $2.6 billion recorded in 2022.
  • Year-over-year, Accounts Payables skyrocketed 51.48% in 2021 and then decreased 15.05% in 2023.
  • Tracing TMO's Accounts Payables over 5 years: stood at $2.9 billion in 2021, then rose by 17.93% to $3.4 billion in 2022, then decreased by 15.05% to $2.9 billion in 2023, then increased by 7.21% to $3.1 billion in 2024, then increased by 17.64% to $3.6 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Accounts Payables are $3.6 billion (Q4 2025), $3.1 billion (Q3 2025), and $3.0 billion (Q2 2025).